Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252979 · ClinicalTrials.gov registry record · Early Phase 1
Ketones & Mitochondrial Heteroplasmy
A Early Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT01252979 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 13 participants.
The verdict
NCT01252979, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The current study is a prospective evaluation of the ability of ketosis to shift mitochondrial DNA (mtDNA) heteroplasmy in subjects harboring a known mutation in their mtDNA at position 3243 (A\>G). Subjects will be given supplemental medium chain triglycerides (MCTs) for a period of 6 months. mtDNA heteroplasmy will be measured 3 months prior to treatment, at treatment initiation, and 6 months after initiation. The primary objective of the current study is to determine if there is a shift in heteroplasmy in patients harboring the 3243 A\>G mtDNA mutation to a more favorable (higher wild-type) profile while in a state of ketosis.
Interventions
- DIETARY_SUPPLEMENT Medium-Chain Triglycerides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01252979
The ClinicalTrials.gov registry entry for NCT01252979 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medium-Chain Triglycerides is the first listed.
NCT01252979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01252979 about?
NCT01252979 is a clinical study titled "Ketones & Mitochondrial Heteroplasmy". The current study is a prospective evaluation of the ability of ketosis to shift mitochondrial DNA (mtDNA) heteroplasmy in subjects harboring a known mutation in their mtDNA at position 3243 (A\>G). Subjects will be given supplemental medium chain triglycerides (MCTs) for a period of 6 months. mtDNA...
What is the current status of trial NCT01252979?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2010-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01252979?
The interventions under investigation include: Medium-Chain Triglycerides (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01252979?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.